Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney EventsDiabetes Care 2020 Sep 10;[EPub Ahead of Print], Y Xie, B Bowe, AK Gibson, JB McGill, Y Yan, G Maddukuri, Z Al-Aly
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.